Analyst Price Targets — URGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 9, 2026 8:21 pm | Amin Makarem | Jefferies | $40.00 | $20.53 | TheFly | UroGen Pharma initiated with a Buy at Jefferies |
| June 13, 2025 10:15 pm | Paul Choi | Goldman Sachs | $16.00 | $12.03 | TheFly | UroGen Pharma price target raised to $16 from $3 at Goldman Sachs |
| June 13, 2025 7:24 pm | Leland Gershell | Oppenheimer | $31.00 | $12.03 | TheFly | UroGen Pharma price target raised to $31 from $10 at Oppenheimer |
| October 14, 2024 7:13 am | Jason Kolbert | EF Hutton | $25.00 | $12.60 | StreetInsider | EF Hutton Starts UroGen Pharma (URGN) at Buy |
| June 14, 2024 8:30 am | Stephen Richardson | Evercore ISI | $46.00 | $20.26 | Benzinga | Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday |
| June 14, 2024 7:43 am | Leland Gershell | Oppenheimer | $40.00 | $17.50 | TheFly | UroGen Pharma price target raised to $40 from $32 at Oppenheimer |
| June 14, 2024 6:14 am | Raghuram Selvaraju | H.C. Wainwright | $60.00 | $17.50 | TheFly | UroGen Pharma price target raised to $60 from $54 at H.C. Wainwright |
| June 14, 2024 5:11 am | Paul Choi | Goldman Sachs | $22.00 | $17.50 | StreetInsider | Goldman Sachs Reiterates Neutral Rating on UroGen Pharma (URGN) |
| May 14, 2024 7:39 am | Leland Gershell | Oppenheimer | $32.00 | $13.07 | StreetInsider | UroGen Pharma (URGN) PT Lowered to $32 at Oppenheimer |
| March 15, 2024 7:23 am | Leland Gershell | Oppenheimer | $34.00 | $14.46 | StreetInsider | UroGen Pharma (URGN) PT Lowered to $34 at Oppenheimer |
Latest News for URGN
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
UroGen Pharma faces a pivotal period as ZUSDURI, its recently approved bladder cancer therapy, is positioned for accelerated adoption following a permanent J-Code in 2026. ZUSDURI's peak sales are anticipated at $1 billion by 2030, with a four-year ramp, but near-term revenue guidance will not be provided until at least Q2–Q3 2026. URGN's liquidity improved to $245.5 million after a revised Pharmakon loan, yet cash…
UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for URGN.
U.S. House Trading
No House trades found for URGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.